Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis
Authors' conclusion
Higher levels of disease activity, tenosynovitis and longer symptom duration prior to rheumatology referral were associated with requiring DMARDs for ICI-inflammatory arthritis, while those treated previously with chemotherapy were less likely to require additional immunosuppression.
Study context
- Population
- Adults with rheumatologist-diagnosed ICI-induced inflammatory arthritis
- Participants
- 126 adults
- Outcome
- Requirement of conventional synthetic (cs) or biologic (b) DMARDs
Methodological detailslogistic regression, adjusted for potential confounders
- Logistic regression
- Adjusted for potential confounders
Main finding
As reported in the abstract
Requirement of csDMARD/bDMARD
Required a csDMARD/bDMARD
53
42%
Observational data: associations, not effects.
Secondary outcomes
Persistent inflammatory arthritis (>6 months after ICI cessation)
- Combination anti-CTLA-4/PD-1 therapy and GC use at baseline associated with higher risk of persistent inflammatory arthritis
Original publication
Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). Published 30 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →